Ra Capital sold its shares in Vor Biopharma (VOR) for $14.5 million. This transaction indicates a significant movement of shares in the biopharma sector. The sale may influence market perception of VOR’s future potential and could affect trading volume. Investors may look for further developments in VOR's performance following this divestment.

Vor Biopharma (VOR) shares sold for $14.5 million by Ra Capital

Craig-Hallum increased its price target for Celcuity to $141 due to advancements in their New Drug Application (NDA). This change reflects the firm’s confidence in the company's developments. The updated target may impact investor sentiment and trading strategies in the biopharmaceutical sector. Celcuity's stock performance and market positioning could be positively influenced by this revision.

biopharma News & Analysis

Market Mood

Vor Biopharma (VOR) shares sold for $14.5 million by Ra Capital

Craig-Hallum Raises Celcuity Stock Price Target to $141 Following NDA Progress